



**THUJA CAPITAL**  
healthcare investors

## **THUJA CAPITAL ADDS DR. MICHEL BRIEJER TO THE INVESTMENT TEAM**

*Utrecht, the Netherlands, April 24, 2008*

Thuja Capital today announces today that Dr. Michel Briejer has joined the investment team as Investment Director, operating from our Utrecht office.

Dr. Briejer comes to Thuja from Crucell (CRXL, Euronext) where he headed as a Senior Program Director the recombinant protein pipeline projects of Crucell, amongst which the Factor V L/C project.

Prior to Crucell, Michel Briejer held senior positions at Janssen Pharmaceutica and Yamanouchi (currently Astellas Pharma) where he gained ample experience in drug research and development.

Harrold van Barlingen, Managing Director of Thuja Capital comments: "Michel is a great addition to the team. He combines a thorough scientific background with in-depth pharma and biotech experience. We are very glad to have him on board."

### *Notes for the editor*

#### **Contact information Thuja Capital**

Harrold van Barlingen Ph.D, Managing Director

☎ + 31 (0)30 253 98 98

✉ [harrold.van.barlingen@thujacapital.com](mailto:harrold.van.barlingen@thujacapital.com)

#### **About Thuja Capital**

[www.thujacapital.com](http://www.thujacapital.com)

Thuja Capital Healthcare Fund (TCHF) is a healthcare dedicated venture capital fund structured to invest in healthcare (life science) innovations with a focus on biopharmaceuticals and medical devices. The investment focus of Thuja Capital Healthcare Fund will be on in privately held early-stage life science companies located in the Benelux, with the goal of achieving a superior return. TCHF is managed by Thuja Capital; Thuja Capital's team believes in building and sustaining a close relationship with the management of companies we invest in. By taking an active role, Thuja Capital aims to help these companies to strengthen and grow their businesses. In addition to this, our broad network of advisors and relationships with other private equity firms allows us to play a significant role in the realization of strategic objectives and additional fundraising.

Furthermore, Thuja Capital is the exclusive manager of AlpInvest Partners' portfolio of early stage life science companies.

#### **About Michel Briejer**

Dr. Michel Briejer joined Thuja Capital early 2008 as an Investment Director. He has gained broad hands-on as well as strategic experience in a variety of senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Moreover, he worked as a consultant for a number of small pharmaceutical and biotech start-up companies in The Netherlands.

Michel strengthens the Thuja team with a wealth of drug development know-how, ranging from chemically synthesized drugs to complex proteins produced by biotechnological methods. Moreover, having been in charge of various drug development programs as a project leader, he understands the complexity of drug development and project management, and has built a large network of specialists.

Michel holds a Master of Science degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (European Center for Pharmaceutical Sciences, Basle). Michel authored over 25 peer reviewed scientific papers and book chapters on pharmacology and drug development.